ABSTRACT
Objective:To assess the evidence for relevant factors associated with mortality in COVID-19 kidney transplantation recipients(KTR) through Meta-analysis.Methods:A complete search of PubMed, Web of Science, Medline, Scopus, Cochrane Library, CNKI and Wanfang Database were performed to search for eligible studies on 18 August 2022.Results:twenty-nine studies involving 7 978 Cases were included in our Meta-analysis.Patients with mean age ≥60 years( OR=1.09, 95% CI: 1.06-1.13), Comorbidities including diabetes mellitus( OR=1.49, 95% CI: 1.26-1.76), cardiovascular disease( OR=1.88, 95% CI: 1.33-2.65), and acute kidney injury( OR=3.46, 95% CI: 1.35-8.89) significantly increased mortality risk.KTR with dyspnea ( OR=2.17, 95% CI: 1.38-3.42), higher Hemoglobin ( OR=1.09, 95% CI: 1.00-1.19), Use of mycophenolic ( OR=1.18, 95% CI: 1.02-1.37) and Antibiotics( OR=7.26, 95% CI: 2.11-25.07) at presentation were at higher mortality risk, while diarrhea( OR=0.57, 95% CI: 0.34-0.96) and higher eGFR( OR=0.95, 95% CI: 0.92-0.98) decreased the risk.Overall in-hospital mortality in COVID-19 KTR was 19%, 95% CI: 15%-23%. Conclusions:Our systematic review and -analysis results suggest that overall in-hospital mortality in COVID-19 KTR declined progressively over time.KTR with these risk factors should receive more intensive monitoring and early therapeutic interventions to optimize health outcomes.
ABSTRACT
Objective To detect the circulating miR-106a levels in serum before and after surgery in patients with renal clear cell carcinoma,and to explore its relationship with clinical-pathological parameters.Methods 30 serum samples from patients with renal clear cell carcinoma were collected before and after surgery during February 2013 to July 2014.This study included 30 normal controls.All serum miR-106a levels were detected using the real-time PCR.Results The serum miR-l06a levels in patients with renal clear cell carcinoma pre-operatively wcre significantly greater than normal controls (Z =-4.251,P =0.0001).The serum miR-106a levels in patients post-operatively had no significant differences compared to normal controls (Z =-0.244,P =0.807).The serum miR-106a levels in post-operative samples were significantly lower than the pre-operative samples (Z =-4.229,P =0.0001).Serum miR-106a levels and other clinical-pathological parameters had no correlation in patients with renal clear cell carcinoma(tumor size:Z =-0.775,P =0.439;Fuhrman grade:Z =-1.694,P =0.090).The receiver operating characteristic curve was used to distinguish pre-operative samples and normal controls,its AUC was 0.819 (95％ CI:0.710-0.929,P =0.0001) with 86.7％ sensitivity and 70.0％ specificity.Conclusions The serum miR-106a levels in patients with renal clear cell carcinoma pre-operatively were significantly greater than post-operatively with no correlation in tumor size and Fuhrman grade.The outcome suggested that serum miR-106a can be regarded as a potential molecular marker in renal clear cell carcinoma.
ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the efficacy and safety of dendritic cell (DC)-based vaccines in the treatment of prostate cancer, and investigate the factors that influence the clinical benefit rate (CBR) of the vaccines.</p><p><b>METHODS</b>Based on pre-determined search criteria, we searched the Medline database for randomized controlled trials on DC-based vaccines immunotherapy of prostate cancer. We systematically analyzed the identified studies using RevMan 5.0 and SPSS 17.0 softwares.</p><p><b>RESULTS</b>Ten randomized controlled trials involving 179 prostate cancer patients were identified and subjected to meta-analysis. The CBR of the DC vaccines for prostate cancer was 54.2% , and the objective response rate was 7.7%. Most adverse effects were local reactions at the injection site, fever and flu-like symptoms. The prostate cancer patients achieved cellular immune response (OR = 31.12, 95% CI = 5.52-175.6, P < 0.01) and reduction of log PSA slope (OR = 4.38, 95% CI = 1.17-16.35, P = 0.03) after administration of DC vaccines, which was positively correlated with CBR. The dose of DC vaccines had a significant correlation with CBR (OR = 5.98, 95% CI = 1.45-24.62, P = 0.01), but not the age of the patients (P = 0.53). Besides, density-enriched DCs achieved a higher CBR, while the route of administration had no effect on CBR.</p><p><b>CONCLUSION</b>DC-based vaccines are effective, safe and well-tolerated in the treatment of prostate cancer. DC-mediated cellular immune response has a significant effect on CBR and can be used as an important index for the assessment of vaccines. More multi-centered randomized controlled trials of higher quality and larger sample size are needed to provide more valid evidence.</p>
Subject(s)
Humans , Male , Cancer Vaccines , Allergy and Immunology , Therapeutic Uses , Dendritic Cells , Allergy and Immunology , Prostatic Neoplasms , Randomized Controlled Trials as TopicABSTRACT
<p><b>OBJECTIVE</b>To investigate the differences in the onset age and pathology of prostate cancer between Uygurs and Hans in Xinjiang.</p><p><b>METHODS</b>We enrolled in this study 518 patients (138 Uygurs and 380 Hans) with prostate cancer confirmed between January 2002 and December 2011. We conducted comparative analyses on their ages, years of diagnosis and Gleason scores.</p><p><b>RESULTS</b>The incidence of prostate cancer increased year by year in both Uygur and Han people, but no statistically significant differences were found in the years of diagnosis between the two groups (chi2 = 1.063, P = 0.900). The median and mode ages of the Uygur patients were 70 and 63 years, and those of the Hans 73 and 71 years. The predilection age of prostate cancer was 70 -79 years in both the two groups. The Uygurs showed a significantly higher incidence of prostate cancer in the 50-59 yr and 60-69 yr groups than the Hans, but the results were just the opposite in the 80-89 yr group (chi2 = 40.375, P = 0.01). The median and mode of Gleason scores were 7 and 6 in the Uygurs, and 8 and 8 in the Hans, respectively, with no significant difference between the two groups (chi2 = 0.991, P = 0.01).</p><p><b>CONCLUSION</b>The Uygurs differed from the Hans in the age of prostate cancer onset, but there were no significant differences in the annually increased incidence and pathological stage of prostate cancer between the Uygurs and Hans in Xinjiang.</p>
Subject(s)
Aged , Aged, 80 and over , Humans , Male , Middle Aged , Age of Onset , Asian People , China , Epidemiology , Ethnicity , Incidence , Prostatic Neoplasms , Epidemiology , EthnologyABSTRACT
<p><b>OBJECTIVE</b>To investigate the indications and clinical effect of using oral mucosa as the graft in hypospadias repair.</p><p><b>METHODS</b>We performed hypospadias repair using oral mucosa for 19 patients, 10 with the urethral opening at the root of the penis, 7 at the scrotum and 2 at the perineum. Of these patients, 8 had received urethroplasty once, and 6 twice, unsuccessfully, and 7 of them were complicated by penile chordee. The lower lip mucosa was used as the graft for 14 cases, and the buccal mucosa for the other 5. Fifteen cases received autologous oral mucosa onlay for repair, with the new urethra covered by the dartos coat of the dorsal skin. For the other 4 cases, whose urethral plates had been damaged in the previous operations, oral mucosa strips were used to substitute the urethral plates to get the penis straightened, followed by urethroplasty 6 months later.</p><p><b>RESULTS</b>Of the 19 patients, 17 (89.5%) achieved satisfactory results, with a desirable shape of the penis and a vertical slit-like meatus at the tip of the glans. Chordee was corrected in all the patients. No urethral stricture was found during the 3 - 18 months follow-up. Urethral fistula occurred in 2 cases because of infection, but cured by surgical repair 6 months later.</p><p><b>CONCLUSION</b>Using oral mucosa as the graft is an effective surgical option for hypospadias repair.</p>